MyPathway trial was one of the clinical trials investigating biological agents that target HER2 amplification in patients with CRC.11 In this study, investigators enrolled patients with mCRC and HER2 amplification regardless of RAS status and investigated the efficacy of trastuzumab and pertuzumab combination. Here, ERBB2 is linked to colorectal carcinoma.